31 May 2006
Lionville, Philadelphia - West Pharmaceutical Services, Inc. has announced a proprietary isoprene-based elastomeric formulation for its needle shields and tip caps. The new formulation out-performs other polyisoprene and natural rubber elastomers by significantly reducing the risk of cracking and provides full compliance with Ph/Eur. Type I and applicable USP standards, said the company.
West said components manufactured with the new formulation are characterised by low coring properties, low levels of extractables and are free of nitrosamines, pre-cursors and natural rubber. The formulation is compatible with steam, gamma and ethylene oxide (EtO) sterilisation and is much less susceptible to frosting or hazing, compared to standard formulations.
In ozone cracking tests, the company continued, components with the new polyisoprene based formulation outperformed other standard polyisoprene or natural rubber elastomers. The new formulation is available in several standard Needle Shield and Tip Cap designs s.
This is an external link and should open in a new window. ERJ is not responsible for the content of external sites.
Website (of West Pharma
Subscribe for unlimited access. A subscription to European Rubber Journal includes:
Already a subscriber? Log in here
